COMPANY:

Myriad Genetics

"Myriad Genetics...announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test. This partnership will leverage Myriad’s advanced laboratory capabilities in the U.S. to support global testing for clinical trials and SOPHiA GENETICS’ broad, decentralized network of more than 800 connected institutions in more than 70 countries for global test deployment."

"Myriad Genetics, Inc...today announced The Lancet Oncology published a study highlighting the performance of Myriad’s molecular residual disease (MRD) test, Precise® MRD, in patients with oligometastatic clear-cell renal cell carcinoma (ccRCC)."

"ANGLE plc...is delighted to announce that it has entered a collaboration with Myriad Genetics, Inc...Under the terms of the agreement, blood samples from cancer patients will be processed by ANGLE's research and development team utilising the Parsortix® system for the capture and harvest of intact cancer cells for downstream molecular analysis. Results for this analysis will compare CTC-DNA with matched patient tissue samples using Myriad Genetics' existing tissue-based assay."

"Myriad Genetics...today announced new molecular residual disease (MRD) clinical data from the MONSTAR-SCREEN 3 study, a collaboration with the National Cancer Center Hospital East (NCCHE) in Japan, demonstrating successful pan-cancer implementation of Myriad’s ultra-sensitive Precise™ MRD Test to detect and monitor ctDNA in patients."

" Myriad Genetics, Inc...announced it will share data from seven new research studies at the 2025 ASCO Annual Meeting, including MRD clinical outcome data from the MONSTAR-SCREEN-3 study. Myriad will also highlight how its comprehensive portfolio of genetic and tumor genomic testing solutions, coupled with its investments in research and product development, are advancing precision oncology and patient care."

"Myriad Genetics...announced today that JCO Precision Oncology published a real-world study suggesting that the results of RiskScore® led clinicians to recommend breast cancer screening aligned with patients’ individual risk. RiskScore, Myriad’s clinically validated breast cancer risk assessment tool integrated into its MyRisk® Hereditary Cancer Test, combines a polygenic risk score (PRS) validated for all ancestries with the widely-used Tyrer-Cuzick model to predict five-year and remaining lifetime risk of breast cancer."

"Myriad Genetics...and PATHOMIQ, Inc...announced that they have entered into a strategic collaboration for Myriad to exclusively license PATHOMIQ_PRAD, PATHOMIQ’s AI technology platform for prostate cancer, in the United States."

"Myriad Genetics...today announced a collaboration with Gabbi, a telehealth solution for breast cancer risk assessment and specialist care services. The companies will work together to provide an integrated offering that combines Gabbi’s risk assessment program and access to breast specialists with Myriad’s MyRisk® with RiskScore® Hereditary Cancer Test"

"Myriad Genetics...announced a study revealing that more patients completed hereditary cancer testing when they used an online screening tool and received education about genetic testing. The study was published in Obstetrics & Gynecology (also known as The Green Journal) and was highlighted in the American College of Obstetricians and Gynecologists (ACOG) Daily Bulletin."

"Myriad Genetics, Inc...announced it will present new data at the 2024 San Antonio Breast Cancer Symposium (SABCS), including a spotlight presentation on a breast cancer risk assessment tool that combines a polygenic score for all ancestries....Additional new data will show how Myriad’s second-generation tumor-informed molecular residual disease (MRD) assay demonstrated high sensitivity, specificity and measurement accuracy, which, together, will facilitate improved resolution in residual-disease detection and extend lead times in recurrence detection...Among the Myriad products highlighted in the company’s SABCS exhibit are: MyRiskHereditary Cancer Test...Precise Tumor Molecular Profile Test...MyChoice CDx...EndoPredict..."

"Myriad Genetics, Inc...announced that its Prolaris prostate cancer prognostic test continues to be classified by the National Comprehensive Cancer Network (NCCN) as an ‘Advanced Tool’ in the fight against prostate cancer. Like other gene expression-based tests, Prolaris for many years has been included in NCCN guidelines with category 2A level of evidence, meaning its inclusion has support from at least 85% of members on the NCCN prostate panel."

"Myriad Genetics, Inc...announced updates to its agreement with Illumina Inc...Myriad’s gold-standard Genomic Instability Score (GIS) to determine Homologous Recombination Deficiency (HRD) will be reported for all samples analyzed with Illumina’s updated research assay, TruSight™ Oncology 500 v2 (TSO 500 v2)."